» Articles » PMID: 32172310

Studies of Insulin and Proinsulin in Pancreas and Serum Support the Existence of Aetiopathological Endotypes of Type 1 Diabetes Associated with Age at Diagnosis

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2020 Mar 16
PMID 32172310
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: It is unclear whether type 1 diabetes is a single disease or if endotypes exist. Our aim was to use a unique collection of pancreas samples recovered soon after disease onset to resolve this issue.

Methods: Immunohistological analysis was used to determine the distribution of proinsulin and insulin in the islets of pancreas samples recovered soon after type 1 diabetes onset (<2 years) from young people diagnosed at age <7 years, 7-12 years and ≥13 years. The patterns were correlated with the insulitis profiles in the inflamed islets of the same groups of individuals. C-peptide levels and the proinsulin:C-peptide ratio were measured in the circulation of a cohort of living patients with longer duration of disease but who were diagnosed in these same age ranges.

Results: Distinct patterns of proinsulin localisation were seen in the islets of people with recent-onset type 1 diabetes, which differed markedly between children diagnosed at <7 years and those diagnosed at ≥13 years. Proinsulin processing was aberrant in most residual insulin-containing islets of the younger group but this was much less evident in the group ≥13 years (p < 0.0001). Among all individuals (including children in the middle [7-12 years] range) aberrant proinsulin processing correlated with the assigned immune cell profiles defined by analysis of the lymphocyte composition of islet infiltrates. C-peptide levels were much lower in individuals diagnosed at <7 years than in those diagnosed at ≥13 years (median <3 pmol/l, IQR <3 to <3 vs 34.5 pmol/l, IQR <3-151; p < 0.0001), while the median proinsulin:C-peptide ratio was increased in those with age of onset <7 years compared with people diagnosed aged ≥13 years (0.18, IQR 0.10-0.31) vs 0.01, IQR 0.009-0.10 pmol/l; p < 0.0001).

Conclusions/interpretation: Among those with type 1 diabetes diagnosed under the age of 30 years, there are histologically distinct endotypes that correlate with age at diagnosis. Recognition of such differences should inform the design of future immunotherapeutic interventions designed to arrest disease progression.

Citing Articles

Single-cell RNA sequencing reveals the dysfunctional characteristics of PBMCs in patients with type 2 diabetes mellitus.

Zhao J, Fang Z Front Immunol. 2025; 15:1501660.

PMID: 39916961 PMC: 11798774. DOI: 10.3389/fimmu.2024.1501660.


Detection of Insulin in Insulin-Deficient Islets of Patients with Type 1 Diabetes.

Krivova Y, Proshchina A, Otlyga D, Kharlamova A, Saveliev S Life (Basel). 2025; 15(1).

PMID: 39860066 PMC: 11766825. DOI: 10.3390/life15010125.


Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes.

Redondo M, Cuthbertson D, Steck A, Herold K, Oram R, Atkinson M Diabetologia. 2024; 68(3):588-601.

PMID: 39670998 PMC: 11832693. DOI: 10.1007/s00125-024-06338-7.


Changes in immunofluorescence staining during islet regeneration in a cystic fibrosis-related diabetes (CFRD) ferret model.

Mohammed S, Bone R, Aquino J, Mirmira R, Evans-Molina C, Ismail H Islets. 2024; 16(1):2436696.

PMID: 39641365 PMC: 11633224. DOI: 10.1080/19382014.2024.2436696.


Genetic Discovery and Risk Prediction for Type 1 Diabetes in Individuals Without High-Risk HLA-DR3/DR4 Haplotypes.

McGrail C, Chiou J, Egamal R, Elgamal R, Luckett A, Oram R Diabetes Care. 2024; 48(2):202-211.

PMID: 39626097 PMC: 11770152. DOI: 10.2337/dc24-1251.


References
1.
Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View

2.
Hagopian W, Ferry Jr R, Sherry N, Carlin D, Bonvini E, Johnson S . Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013; 62(11):3901-8. PMC: 3806608. DOI: 10.2337/db13-0236. View

3.
Thomas N, Jones S, Weedon M, Shields B, Oram R, Hattersley A . Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. 2017; 6(2):122-129. PMC: 5805861. DOI: 10.1016/S2213-8587(17)30362-5. View

4.
Redondo M, Concannon P . Genetics of Type 1 Diabetes Comes of Age. Diabetes Care. 2019; 43(1):16-18. PMC: 6925580. DOI: 10.2337/dci19-0049. View

5.
Battaglia M, Atkinson M . The streetlight effect in type 1 diabetes. Diabetes. 2015; 64(4):1081-90. PMC: 4375074. DOI: 10.2337/db14-1208. View